\u00a0<\/p>\n
Title: Identificaci\u00f3n de los cirRNA y lncRNA que regulan la firma de miRNA de respuesta al tratamiento en pacientes con hepatocarcinoma avanzado. Desarrollo de una herramienta experimental<\/p>\n
Funding Entity: Instituto de Salud Carlos III (PI22\/00857)<\/p>\n
Duration: 2023-2025<\/p>\n
Principal Investigator: Jordi Muntan\u00e9 Relat<\/p>\n
Granted: 147.317,50 Euros<\/p>\n
\u00a0<\/p>\n
Title: Converting molecular profiles of myeloid cells into biomarkers for inflammation and cancer (Mye-InfoBank)<\/p>\n
Funding Entity: EU Framework Programme-Horizon 2020 (COST Action CA20117)<\/p>\n
Duration: 2021-2024<\/p>\n
Principal Investigator: Sven Brandau<\/p>\n
Management Committee: Jordi Muntan\u00e9 Relat y Concepci\u00f3n Mara\u00f1\u00f3n Lizana<\/p>\n
Working group: WG 2 Mye-SOP y WG 3 Mye-Disease<\/p>\n
Granted: 580.000 Euros<\/p>\n
\u00a0<\/p>\n
Title: Bench to bedside transition for pharmacologicalregulation diseasesregulation of NRF2 in noncommunicable diseases (BenBedPhar)<\/p>\n
Funding Entity: EU Framework Program-Horizon 2020 (COST Action CA20121)<\/p>\n
Duration: 2021-2024<\/p>\n
Principal Investigator: Antonio Cuadrado<\/p>\n
Management Committee (Spain): Manuela Garc\u00eda L\u00f3pez y Ana Isabel Rojo<\/p>\n
Working groups: WG2 Pharmacological regulation and drugs and WP3 Translation medicine<\/p>\n
Granted: 580.000 Euros<\/p>\n
\u00a0<\/p>\n
Title: Aislamiento y criopreservaci\u00f3n de hepatocitos humanos \u00fatiles para la validaci\u00f3n de la actividad de los inhibidores de tirosina quinasa en el metabolismo celular y en los mecanismos de supervivencia y muerte celular<\/p>\n
Financial Entity: Consejer\u00eda de Salud y Familias, Convocatoria Proyectos de investigaci\u00f3n e innovaci\u00f3n colaboraci\u00f3n p\u00fablico-privada (PIP-0215-2020)<\/p>\n
Duration: 2021-2023<\/p>\n
Principal investigator: Miguel \u00c1ngel G\u00f3mez Bravo<\/p>\n
Granted: 243.788,50 Euros<\/p>\n
\u00a0<\/p>\n
Title: Identificaci\u00f3n del papel de miRNA y lncRNA en las c\u00e9lulas tumorales circulantes en la progresi\u00f3n y respuesta al tratamiento en pacientes con carcinoma hepatocelular en estadio intermedio y avanzado. Desarrollo de una nueva terapia experimental<\/p>\n
Financial Entity: Consejer\u00eda de Salud y Familias, Convocatoria Proyectos de investigaci\u00f3n en salud (PI-0216-2020)<\/p>\n
Duration: 2021-2023<\/p>\n
Principal Investigator: Jordi Muntan\u00e9 Relat, Mar\u00eda Teresa Ferrer R\u00edos<\/p>\n
Granted: 149.508,05 Euros<\/p>\n
\u00a0<\/p>\n
Title: Functional impact of epigenetic regulation in hepatocarcinoma: Development of combined nanovectorization of miRNAs\/lncRNAs and drugs useful in experimental liver cancer model<\/p>\n
Financial Entity: Instituto de Salud Carlos III (PI19\/01266)<\/p>\n
Duration: 2020-2022<\/p>\n
Principal Investigator: Jordi Muntan\u00e9 Relat<\/p>\n
Granted: 165.770,00 Euros<\/p>\n
\u00a0<\/p>\n
Title: Biolog\u00eda y Medicina Redox<\/p>\n
Financial Entity: Convocatoria 2018 \u2010 Acciones de dinamizaci\u00f3n \u00abRedes de Investigaci\u00f3n\u00bb (RED2018\u2010102576\u2010T)<\/p>\n
Duration: 2020-2021<\/p>\n
Principal Investigator: Juan Sastre Belloch<\/p>\n
Granted: 20.500 Euros<\/p>\n
\u00a0<\/p>\n
Title: Liquid Biopsy applied to the search for cellular and epigenetic markers for the development of diagnostic, prognostic and predictive tests in patients with hepatocarcinoma (PC-0033-2017)<\/p>\n
Financial Entity: Consejer\u00eda de Salud (Junta de Andaluc\u00eda)<\/p>\n
Duration: 2018-2020<\/p>\n
Principal Investigator: Jos\u00e9 Antonio Lorente Acosta<\/p>\n
Granted: 66.065,38 Euros<\/p>\n
\u00a0<\/p>\n
Title: In vitro 3-D total cell guidance and fitness (COST Action CA16119 CellFit)<\/p>\n
Financial Entity: COST Action CA16119<\/p>\n
Duration: 2017-2021<\/p>\n
Principal Investigator: Tiziana Brevini<\/p>\n
Working groups: WG1 3-D Cultures and Bioprinting; WG3 Chemobiological cues and Epigenetic controls<\/p>\n
Granted: 580.000 Euros<\/p>\n
\u00a0<\/p>\n
Project Title: Genetic, transcriptomic and proteomic markers related to the evolution of hepatocarcinoma, co-morbidities and response to treatments (PI16\/00090)<\/p>\n
Financial Entity: Instituto de Salud Carlos III<\/p>\n
Duration: 2017-2019<\/p>\n
Principal Investigator: Jordi Muntan\u00e9 Relat<\/p>\n
Granted: 152.460 Euros<\/p>\n
\u00a0<\/p>\n
Title: Extracellular vesicle secretion and its relationship with the evolution of hepatocarcinoma, co-morbidities and response to treatments: Clinical and experimental study (PI-0198-2016)<\/p>\n
Financial Entity: Consejer\u00eda de Salud<\/p>\n
Duration: 2017-2019<\/p>\n
Principal Investigator: Raul Gonz\u00e1lez Ojeda<\/p>\n
Granted: 57.465,49 Euros<\/p>\n
\u00a0<\/p>\n
Title: Stratification of patients with hepatocarcinoma based on the detection and genetic and phenotypic analysis of CTCs: relationship with clinical evolution and response to treatment (PC-0522-2016-0043)<\/p>\n
Financial Entity: Consejer\u00eda de Salud<\/p>\n
Duration: 2017-2019<\/p>\n
Principal Investigator: Jos\u00e9 Mar\u00eda \u00c1lamo<\/p>\n
Granted: 16.100 Euros<\/p>\n
\u00a0<\/p>\n
Title: European Network of Multidisciplinary Research and Translation of Autophagy knowledge (TRANSAUTOPHAGY)<\/p>\n
Financial Entity: COST Action CA15138<\/p>\n
Duration: 2016-2020<\/p>\n
Principal Investigator: Caty Casas<\/p>\n
Working groups: WG1: Basic Research on Autophagy Molecular Machinery; WG4: Biomedical Research (iv Cancer).<\/p>\n
Granted: 560.000 Euros<\/p>\n
\u00a0<\/p>\n
Project Title: Mitochondrial mapping: Evolution-Age-Gender-Lifestyle-Environment (MITOEAGLE)<\/p>\n
Financial Entity: COST Action CA15203)<\/p>\n
Duration: 2016-2020<\/p>\n
Principal Investigator: Erich Gnaiger<\/p>\n
Working groups: TG3.2 Liver and TG4.2 Cultured cells.<\/p>\n
Granted: 540.000 Euros<\/p>\n
\u00a0<\/p>\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
\u00a0 Title: Identificaci\u00f3n de los cirRNA y lncRNA que regulan la firma de miRNA de respuesta al tratamiento en pacientes con hepatocarcinoma avanzado. Desarrollo de […]<\/a><\/p>\n<\/div>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-full.php","meta":{"footnotes":""},"class_list":["post-118","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/liverresearchunit.org\/index.php?rest_route=\/wp\/v2\/pages\/118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/liverresearchunit.org\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/liverresearchunit.org\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/liverresearchunit.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/liverresearchunit.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=118"}],"version-history":[{"count":10,"href":"https:\/\/liverresearchunit.org\/index.php?rest_route=\/wp\/v2\/pages\/118\/revisions"}],"predecessor-version":[{"id":427,"href":"https:\/\/liverresearchunit.org\/index.php?rest_route=\/wp\/v2\/pages\/118\/revisions\/427"}],"wp:attachment":[{"href":"https:\/\/liverresearchunit.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}